

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **China Grand Pharmaceutical and Healthcare Holdings Limited**

**遠大醫藥健康控股有限公司\***

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 00512)**

### **VOLUNTARY ANNOUNCEMENT CFIUS CLEARANCE OF SIRTEX ACQUISITION**

The Board of Directors (the “**Board**”) of China Grand Pharmaceutical and Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”), is pleased to report today, on a voluntary basis, that on 11 March 2019 (U.S. time), the Committee on Foreign Investment in the United States (“**CFIUS**”) concluded all action under relevant law and cleared the acquisition of Sirtex Medical Limited (“**Sirtex**”) by the Group and CDH Genetech Limited (“**CDH Genetech**”) (the “**Acquisition**”). CFIUS determined, following receipt of certain assurances from the parties to the Acquisition, that there were no unresolved national security concerns with respect to the Acquisition.

Reference is made to the announcement of the Company dated 14 June 2018 in relation to the acquisition of 100% of the shares of Sirtex by the Group and CDH Genetech. The Group, CDH Genetech and Sirtex entered into the binding scheme implementation deed (the “**Deed**”), the terms of which included the submission of a joint voluntary notification of the Acquisition to CFIUS for its consideration.

The Group’s strong track record for compliance with laws and regulations in the jurisdictions in which it operates, as reflected in the CFIUS clearance and other regulatory authorizations in connection with the Acquisition, provides the Group with a solid foundation for the future, and affords the Group a strong basis for exploring future investment and acquisition activities in relevant markets.

Through its participation in the Acquisition, the Group has gained introduction into the field of liver cancer treatment. Sirtex’s SIR-Spheres Y-90 resin microspheres are used in treatments throughout the world. Over 1,160 treatment centers worldwide have delivered more than 86,000 doses. Currently China alone accounts for over half of the world’s population of liver cancer patients, representing a significant market opportunity for the Sirtex therapy. The Group has assisted Sirtex to kick-off the commercialization in China so as to bring its leading therapeutic solution to Chinese patients in need. In recent years, the Chinese medical authority has continuously issued a number of preferential policies to support, promote and accelerate the introduction and registration of medicines with international innovative characteristics and therapeutic products to acute diseases which market urgently need. The Group believes these policies would benefit the registration and

approval processes of product of Sirtex, and accelerate the launch and commercialization procedures in China.

The Group is following a development strategy of technology innovation and development internationally. In recent years the Group has participated in international investment and acquisition activities with the aim to introduce international innovative treatment methods and products with market development potential into the China market. With the assistance of the Group's leading position in the cerebro-cardiovascular and ENT sectors and the sales network covering the nation, it can efficiently introduce international innovative products into the China market and leverage the Group's existing resources, providing important new and innovative treatment options to patients. This strategy has the potential to enhance the core competitiveness and operational efficiency of the Group and bring fruitful returns to shareholders.

The Company will make further announcements following any material developments with respect to the Acquisition.

By order of the Board  
**China Grand Pharmaceutical and  
Healthcare Holdings Limited**  
**Liu Chengwei**  
*Chairman*

Hong Kong, 12 March 2019

*As at the date of this announcement, the Board comprises four executive directors, namely, Mr. Liu Chengwei, Mr. Hu Bo, Dr. Shao Yan and Dr. Niu Zhanqi and three independent non-executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Pei Geng and Mr. Hu Yebi.*

*\* For identification purpose only*